BS_2W3NC4K1
Neurofibroma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Neurofibroma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Neurofibroma
- overall_survival_months
- 193.49540078843626
- age_years
- 4.742
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.752
- INTERFERON_GAMMA_RESPONSE+0.696
- ALLOGRAFT_REJECTION+0.603
- IL6_JAK_STAT3_SIGNALING+0.556
- INFLAMMATORY_RESPONSE+0.552
- TNFA_SIGNALING_VIA_NFKB+0.509
- IL2_STAT5_SIGNALING+0.445
- COAGULATION+0.427
- APOPTOSIS+0.425
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.408
Top 10 suppressed
- E2F_TARGETS-0.388
- PANCREAS_BETA_CELLS-0.344
- G2M_CHECKPOINT-0.302
- SPERMATOGENESIS-0.288
- OXIDATIVE_PHOSPHORYLATION-0.221
- MTORC1_SIGNALING-0.162
- PROTEIN_SECRETION-0.148
- MYC_TARGETS_V1-0.126
- HEDGEHOG_SIGNALING-0.111
- FATTY_ACID_METABOLISM-0.088
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_893A91ZM | Neurofibroma | — | 0.976 |
| 2 | BS_RQSKD7PN | MPNST | — | 0.948 |
| 3 | BS_3Y0QXZQB | Neurofibroma | — | 0.936 |
| 4 | BS_B7QS4DHK | Schwannoma | — | 0.934 |
| 5 | BS_Y3G1X98S | Meningioma | — | 0.934 |
| 6 | BS_0RF0EZTV | Neurofibroma | — | 0.931 |
| 7 | BS_NDRDM2A9 | Neurofibroma | — | 0.929 |
| 8 | BS_9HA238XS | Neurofibroma | — | 0.911 |
| 9 | BS_49VCQD19 | Neurofibroma | — | 0.911 |
| 10 | BS_Z9ZS6ZS2 | MPNST | — | 0.906 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.752 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.696 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.603 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.556 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.552 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.509 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.445 | Idelalisib | — uncovered |
| COAGULATION | 0.427 | Binimetinib | — uncovered |
| APOPTOSIS | 0.425 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.408 | Inavolisib | — uncovered |
| COMPLEMENT | 0.406 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.376 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.375 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.359 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.343 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.325 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.313 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.281 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.266 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.259 | Inavolisib | — uncovered |